biotech · Type 1 Diabetes Mellitus · Dehydration · HALO
HALOZYME THERAPEUTICS
HALOZYME THERAPEUTICS, INC.
HALOZYME THERAPEUTICS is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker HALO. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Dehydration, Pancreatic Ductal Adeno
12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
- Status
- Public
- HQ
- 12390 El Camino Real, San Diego, California 92130, US
- Founded
- 2021
- Employees
- 530
- Programs
- 45
- Drugs
- 33
- Patents
- 70
Atezolizumab
Phase 2 · small molecule · Pancreatic Ductal Adenocarcinoma
Atezolizumab for Pancreatic Ductal Adenocarcinoma is a Phase 2 program (small_molecule) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code AAAS1908
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- HALOZYME THERAPEUTICS, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Pancreatic Ductal Adenocarcinoma
- Status
- terminated
- Trials
- 1